Results 151 to 160 of about 21,798 (199)
Some of the next articles are maybe not open access.
Myelofibrosis in neuroblastoma
Medical and Pediatric Oncology, 1982AbstractMyelofibrosis, a rare childhood disorder, has been reported as an associated complication of certain hematologic malignancies or as an isolated idiopathic process. In this report, we describe a patient with metastatic neuroblastoma whose initial presentation included the findings of myelofibrosis and leukoery‐throblastosis.
R J, Labotka, E R, Morgan
openaire +2 more sources
Hematology, 2011
AbstractMyelofibrosis (MF), either primary or arising from previous polycythemia vera (PV) or essential thrombocythemia (ET), is the worst among the chronic myeloproliferative neoplasms in terms of survival and quality of life. Patients with MF have to face several clinical issues that, because of the poor effectiveness of medical therapy, surgery or ...
openaire +4 more sources
AbstractMyelofibrosis (MF), either primary or arising from previous polycythemia vera (PV) or essential thrombocythemia (ET), is the worst among the chronic myeloproliferative neoplasms in terms of survival and quality of life. Patients with MF have to face several clinical issues that, because of the poor effectiveness of medical therapy, surgery or ...
openaire +4 more sources
American Journal of Clinical Pathology, 1982
This report describes a 20-year-old patient with rapidly fatal fibrosis of the bone marrow associated with leukopenia, anemia, and large number of myeloblasts in peripheral blood. The bone marrow revealed extensive fibrosis and hyperplasia of the myeloblasts and megakaryocytes.
openaire +2 more sources
This report describes a 20-year-old patient with rapidly fatal fibrosis of the bone marrow associated with leukopenia, anemia, and large number of myeloblasts in peripheral blood. The bone marrow revealed extensive fibrosis and hyperplasia of the myeloblasts and megakaryocytes.
openaire +2 more sources
Expert Opinion on Pharmacotherapy
Myelofibrosis (MF) is a hematologic disease characterized by bone marrow fibrosis, cytopenias, splenomegaly, and constitutional symptoms. Recent years have seen the emergence of novel therapeutic agents, notably ruxolitinib and fedratinib, which target the Janus kinases (JAK) pathway. However, their myelosuppressive effect coupled with the persistence,
Bruzzese, Antonella +11 more
openaire +2 more sources
Myelofibrosis (MF) is a hematologic disease characterized by bone marrow fibrosis, cytopenias, splenomegaly, and constitutional symptoms. Recent years have seen the emergence of novel therapeutic agents, notably ruxolitinib and fedratinib, which target the Janus kinases (JAK) pathway. However, their myelosuppressive effect coupled with the persistence,
Bruzzese, Antonella +11 more
openaire +2 more sources
Myelofibrosis: pathogenesis of myelofibrosis with myeloid metaplasia
Springer Seminars in Immunopathology, 2000M. C. Le Bousse-Kerdil�s +2 more
openaire +2 more sources
Association between myelofibrosis and thromboembolism: A population‐based retrospective cohort study
Journal of Thrombosis and Haemostasis, 2020, Gad Rennert
exaly